Figure 2: Post-exposure treatment of EBOV-infected NHPs with purified anti-EBOV GP equine IgG. | Scientific Reports

Figure 2: Post-exposure treatment of EBOV-infected NHPs with purified anti-EBOV GP equine IgG.

From: Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG

Figure 2

Cynomolgus macaques (Macaca fascicularis) were infected with 1000 PFU of EBOV. The first equine IgG treatment (20 ml intravenously) was given 24 h post-infection (day 1) followed by daily treatments for 4 days (20 ml intravenously), with NHP2 and NHP3 receiving an additional treatment (5 ml intravenously) on day 13 post-infection. (a) EBOV RNA (RNAemia) levels in the Control and IgG-treated NHPs expressed in PFU equivalents per ml of serum (see Materials and Methods). Red cross in the Control shows time of death. (b) Body temperature of Control and IgG-treated NHPs. Red boxes represent ≥1.5 °C fever. (c) ALT and AST levels in Control and IgG-treated NHPs. Red boxes represent values above the normal range. (d) Analysis of anti-GP antibody responses by ELISA assays; total anti-GP antibody titers (top panels) and NHP anti-GP titers (bottom panels). Yellow boxes illustrate periods when equine GP-specific IgG, but not NHP GP-specific IgG, were detected.

Back to article page